NICE Again Rejects Xarelto, This Time In DVT Indications

13 Mar 2012

• By John Davis

U.K. cost watchdog NICE asks for further data on use of Bayer's Xarelto for the treatment and prevention of deep vein thrombosis, having made similar demands at the start of the year on its use in atrial fibrillation.

The National Institute for Health and Clinical Excellence (NICE) says it will reject the use of Bayer AG's oral anticoagulant Xarelto (rivaroxaban) for the treatment and prevention of deep vein thrombosis unless it receives further analyses of the drug’s use in certain subgroups, or as a long-term therapy.

Rivaroxaban, developed in collaboration with Johnson & Johnson which markets it in the U.S., costs 100 times more to...